Polymeric vectors for ocular gene delivery

Therapeutic Delivery

Volumn 2, Issue 4, 2011, Pages 523-536

  Tamboli, Viral ^a   Mishra, Gyan P ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CHITOSAN; CYTOKERATIN 12; DEOXYRIBONUCLEASE I; HYALURONIC ACID; KERATOCAN; LIPOPLEX; MACROGOL; NANOPARTICLE; OLIGONUCLEOTIDE; POLYETHYLENEIMINE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYLYSINE; POLYPROPYLENE;

BIOCOMPATIBILITY; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CELL NUCLEUS; CHEMICAL MODIFICATION; ELECTROPORATION; ENDOSOME; EYE DISEASE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; LYSOSOME; MOLECULAR WEIGHT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; ULTRASOUND; VITREOUS BODY;

EID: 79954531802     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.20     Document Type: Review

References (106)

1. Wu TL, Ertl HC. Immune barriers to successful gene therapy. Trends Mol. Med. 15, 32-39 (2009).
2. Chaum E, Hatton MP. Gene therapy for genetic and acquired retinal diseases. Surv. Ophthalmol. 47, 449-469 (2002). (Pubitemid 35341619)
3. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog. Retin. Eye Res. 24, 537-559 (2005).
4. Acland GM, Aguirre GD, Ray J et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95 (2001). (Pubitemid 32405824)
5. Acland GM, Aguirre GD, Bennett J et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol. Ther. 12, 1072-1082 (2005). (Pubitemid 41723041)
6. Bainbridge JW, Ali RR. Keeping an eye on clinical trials in 2008. Gene Ther. 15, 633-634 (2008).
7. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11(Suppl. 1), S10-S17 (2004). (Pubitemid 39359442)
8. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 10, 955-963 (2003). (Pubitemid 36722430)
9. Provost N, Le Meur G, Weber M et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11, 275-283 (2005).
10. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60, 249-271 (2000).
11. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol. Ther. 2, 302-317 (2000).
12. Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv. Drug Deliv. Rev. 58, 1224-1242 (2006). (Pubitemid 44794428)
13. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy. J. Control Release. 124, 107-133 (2007). (Pubitemid 350101883)
14. Yusifov TN, Abduragimov AR, Narsinh K, Gasymov OK, Glasgow BJ. Tear lipocalin is the major endonuclease in tears. Mol. Vis. 14, 180-188 (2008). (Pubitemid 351193999)
15. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37, 435-456 (1993). (Pubitemid 23144013)
16. Bertelmann E, Jaroszewski J, Pleyer U. Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica 216, 2-12 (2002). (Pubitemid 34252980)
17. Poulaki V, Colby K. Genetics of anterior and stromal corneal dystrophies. Semin. Ophthalmol. 23, 9-17 (2008). (Pubitemid 351156988)
18. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr. Opin. Ophthalmol. 12, 242-249 (2001). (Pubitemid 32751680)
19. Carr DJ, Harle P, Gebhardt BM. The immune response to ocular herpes simplex virus type 1 infection. Exp. Biol. Med. (Maywood).226, 353-366 (2001). (Pubitemid 32506362)
20. Williams KA, Coster DJ. Gene therapy for diseases of the cornea - a review. Clin. Experiment Ophthalmol. 38, 93-103 (2010).
21. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye (Lond).17, 906-911 (2003). (Pubitemid 37541043)
22. Mishra GP, Gaudana R, Tamboli VM, Mitra AK. Recent advances in ocular drug delivery: role of transporters, receptors, and nanocarriers. In:Targeted Delivery of Small and Macromolecular Drugs . Maharo RI, Narang AS (Eds).Taylor and Francis, NY, USA, 421-456 (2010).
23. Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. Ophthalmol. Vis. Sci. 38, 627-634 (1997). (Pubitemid 27143133)
24. Kamata Y, Okuyama T, Kosuga M et al. Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. Mol. Ther. 4, 307-312 (2001). (Pubitemid 33040514)
25. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 60, 207-225 (2005). (Pubitemid 40804562)
26. Liaw J, Chang SF, Hsiao FC. In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO- PEO) polymeric micelles. Gene Ther. 8, 999-1004 (2001). (Pubitemid 32633376)
27. Tong YC, Chang SF, Liu CY, Kao WW, Huang CH, Liaw J. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J. Gene Med. 9, 956-966 (2007). (Pubitemid 350104410)
28. de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther. 15, 668-676 (2008). (Pubitemid 351524521)
29. Hao J, Li SK, Kao WW, Liu CY. Gene delivery to cornea. Brain Res. Bull. 81, 256-261 (2010).
30. George AJ, Arancibia-Carcamo CV, Awad HM et al. Gene delivery to the corneal endothelium. Am. J. Respir. Crit. Care Med. 162, S194-S200 (2000).
31. Collins L, Fabre JW. A synthetic peptide vector system for optimal gene delivery to corneal endothelium. J. Gene Med. 6, 185-194 (2004). (Pubitemid 40228037)
32. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 3, 45-56 (2003). (Pubitemid 36193650)
33. Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: focus on non-viral approaches. Drug Discov. Today. 14, 306-315 (2009).
34. Bochot A, Fattal E, Boutet V et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest. Ophthalmol. Vis. Sci. 43, 253-259 (2002). (Pubitemid 34032467)
35. Bennett J, Maguire AM, Cideciyan AV et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc. Natl Acad. Sci. USA 96, 9920-9925 (1999). (Pubitemid 29398833)
36. Bishop P. The biochemical structure of mammalian vitreous. Eye (Lond).10(Pt 6), 664-670 (1996). (Pubitemid 27037556)
37. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. 20, 576-583 (2003). (Pubitemid 36438900)
38. Peeters L, Sanders NN, Braeckmans K et al. Vitreous: a barrier to nonviral ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 46, 3553-3561 (2005). (Pubitemid 44264656)
39. Pitkanen L, Pelkonen J, Ruponen M, Ronkko S, Urtti A. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J. 6, e25 (2004).
40. Borras T. Recent developments in ocular gene therapy. Exp. Eye Res. 76, 643-652 (2003). (Pubitemid 36549021)
41. Kang HC, Lee M, Bae YH. Polymeric gene carriers. Crit. Rev. Eukaryot. Gene Expr. 15, 317-342 (2005).
42. He CX, Tabata Y, Gao JQ. Non-viral gene delivery carrier and its three-dimensional transfection system. Int. J. Pharm. 386, 232-242 (2010).
43. Perales JC, Ferkol T, Molas M, Hanson RW. An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur. J. Biochem. 226, 255-266 (1994). (Pubitemid 24379043)
44. Pouton CW, Uduehi AN, Milroy DA, Lucas P. Cellular interaction and fate of polycationn&tild;DNA complexes. In:Self- Assembling Complexes for Gene Delivery. Kabanov AV, Felgner P, Seymour LW (Eds).Wiley, NY, USA, 255-273 (1998).
45. Sun X, Zhang N. Cationic polymer optimization for efficient gene delivery. Mini Rev. Med. Chem. 10, 108-125 (2010).
46. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl Acad. Sci. USA 91, 4086-4090 (1994). (Pubitemid 24139578)
47. Garcia-Valenzuela E, Rayanade R, Perales JC, Davidson CA, Hanson RW, Sharma SC. Axon-mediated gene transfer of retinal ganglion cells in vivo. J. Neurobiol. 32, 111-122 (1997). (Pubitemid 27020249)
48. Mannisto M, Vanderkerken S, Toncheva V et al. Structure-activity relationships of poly(l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J. Control Rel. 83, 169-182 (2002). (Pubitemid 35239824)
49. Mannisto M, Ronkko S, Matto M et al. The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment epithelial cell line. J. Gene Med. 7, 466-476 (2005). (Pubitemid 40553127)
50. Farrell LL, Pepin J, Kucharski C, Lin X, Xu Z, Uludag H. A comparison of the effectiveness of cationic polymers poly-l-lysine (PLL) and polyethylenimine (PEI) for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC).Eur. J. Pharm. Biopharm. 65, 388-397 (2007).
51. Midoux P, Monsigny M. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug. Chem. 10, 406-411 (1999). (Pubitemid 29243322)
52. Kwoh DY, Coffin CC, Lollo CP et al. Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim. Biophys Acta. 1444, 171-190 (1999). (Pubitemid 29104831)
53. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 40, 159-170 (2010).
54. Yamazaki M, Ito T. Deformation and instability in membrane structure of phospholipid vesicles caused by osmophobic association: mechanical stress model for the mechanism of poly(ethylene glycol)-induced membrane fusion. Biochemistry 29, 1309-1314 (1990). (Pubitemid 20053856)
55. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One. 1, e38 (2006).
56. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 4, e5290 (2009).
57. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Chitosan and its role in ocular therapeutics. Mini. Rev. Med. Chem. 9, 1639-1647 (2009).
58. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J. Pharm. Pharmacol. 55, 1451-1463 (2003). (Pubitemid 37441350)
59. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 62, 12-27 (2010).
60. Huang M, Fong CW, Khor E, Lim LY. Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J. Control. Release 106, 391-406 (2005). (Pubitemid 41187448)
61. Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El Dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res. 31, 1040-1049 (2008).
62. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224, 159-168 (2001). (Pubitemid 32706495)
63. Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vector-mediated gene delivery. Biotechnol. J. 4, 1559-1572 (2009).
64. Borchard G. Chitosans for gene delivery. Adv. Drug Deliv. Rev. 52, 145-150 (2001). (Pubitemid 33079170)
65. Sato T, Ishii T, Okahata Y. In vitro gene delivery mediated by chitosan. effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials 22, 2075-2080 (2001). (Pubitemid 32738750)
66. Mao HQ, Roy K, Troung-Le VL et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control Release 70, 399-421 (2001). (Pubitemid 32155463)
67. Nimesh S, Thibault MM, Lavertu M, Buschmann MD. Enhanced gene delivery mediated by low molecular weight chitosan/DNA complexes: effect of pH and serum. Mol. Biotechnol. 46, 182-196 (2010).
68. Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27, 4815-4824 (2006). (Pubitemid 43880352)
69. de la Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv. Drug Deliv. Rev. 62, 100-117 (2010).
70. Prow TW, Bhutto I, Kim SY et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 4, 340-349 (2008).
71. Paolicelli P, de la Fuente M, Sanchez A, Seijo B, Alonso MJ. Chitosan nanoparticles for drug delivery to the eye. Expert Opin. Drug Deliv. 6, 239-253 (2009).
72. Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 57, 1-8 (2004). (Pubitemid 38058799)
73. Aragona P. Hyaluronan in the treatment of ocular surface disorders. In:Chemistry and Biology of Hyaluronan . Garga HG, Hales CA (Eds).Elsevier Ltd, Oxford, UK, 529-551 (2004).
74. Lerner LE, Schwartz DM, Hwang DG, Howes EL, Stern R. Hyaluronan and CD44 in the human cornea and limbal conjunctiva. Exp. Eye Res. 67, 481-484 (1998). (Pubitemid 28552970)
75. de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 49, 2016-2024 (2008).
76. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297-7301 (1995).
77. Ogris M. Gene delivery using polyethylenimine and copolymers. Polymeric gene delivery. In:Principles and Applications. Amiji MM (Ed.).CRC press, FL, USA, 97-106 (2005).
78. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7, 657-663 (2005). (Pubitemid 40744532)
79. von Harpe A, Petersen H, Li Y, Kissel T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release. 69, 309-322 (2000).
80. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16, 1273-1279 (1999). (Pubitemid 29393618)
81. Oh YK, Suh D, Kim JM, Choi HG, Shin K, Ko JJ. Polyethylenimine-mediated cellular uptake, nucleus trafficking and expression of cytokine plasmid DNA. Gene Ther. 9, 1627-1632 (2002). (Pubitemid 35414525)
82. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60, 247-266 (2005). (Pubitemid 40804565)
83. Reinisalo M, Urtti A, Honkakoski P. Freeze-drying of cationic polymer DNA complexes enables their long-term storage and reverse transfection of post-mitotic cells. J. Control. Release. 110, 437-443 (2006). (Pubitemid 41827498)
84. Gomes dos Santos AL, Bochot A, Tsapis N et al. Oligonucleotide- polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFb-2 therapy. Pharm. Res. 23, 770-781 (2006).
85. Kuo CN, Yang LC, Wu PC, Kuo HK, Kuo CJ, Tai MH. Dehydrated form of plasmid expressing basic fibroblast growth factor-polyethylenimine complex is a novel and accurate method for gene transfer to the cornea. Curr. Eye Res. 30, 1015-1024 (2005).
86. Nguyen TH, Murakami A, Fujiki K, Kanai A. Transferrin-polyethylenimine conjugate, FuGENE6 and TransIT-LT as nonviral vectors for gene transfer to the corneal endothelium. Jpn. J. Ophthalmol. 46, 140-146 (2002). (Pubitemid 34309027)
87. Horbinski C, Stachowiak MK, Higgins D, Finnegan SG. Polyethyleneimine- mediated transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina. BMC Neurosci. 2, 2 (2001).
88. White JB, Taylor RE, Pittler SJ. Reproducible high efficiency gene transfer into Y79 retinoblastoma cells using adenofection. J. Neurosci. Methods 106, 1-7 (2001). (Pubitemid 32193009)
89. Fattal E, De Rosa G, Bochot A. Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acids. Int. J. Pharm. 277, 25-30 (2004). (Pubitemid 38670418)
90. Hyon SH. Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med. J. 41, 720-734 (2000).
91. Zou W, Liu C, Chen Z, Zhang N. Preparation and characterization of cationic PLA-PEG nanoparticles for delivery of plasmid DNA. Nanoscale Res. Lett. 4, 982-992 (2009).
92. Kimura H, Ogura Y, Moritera T, Honda Y, Tabata Y, Ikada Y. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr. Eye Res. 13, 353-360 (1994). (Pubitemid 24148117)
93. Giordano GG, Thomson RC, Ishaug SL et al. Retinal pigment epithelium cells cultured on synthetic biodegradable polymers. J. Biomed. Mater. Res. 34, 87-93 (1997). (Pubitemid 26425222)
94. Moritera T, Ogura Y, Yoshimura N et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 33, 3125-3130 (1992).
95. Bourges JL, Gautier SE, Delie F et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44, 3562-3569 (2003). (Pubitemid 36909796)
96. Basarkar A, Devineni D, Palaniappan R, Singh J. Preparation, characterization, cytotoxicity and transfection efficiency of poly(dl-lactide-co-glycolide) and poly(dl-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int. J. Pharm. 343, 247-254 (2007). (Pubitemid 47334869)
97. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16, 1217-1226 (2002). (Pubitemid 34815409)
98. Bejjani RA, BenEzra D, Cohen H et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11, 124-132 (2005). (Pubitemid 41358300)
99. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release 126, 97-110 (2008).
100. Chen J, Tian B, Yin X et al. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems. J. Biotechnol. 130, 107-113 (2007). (Pubitemid 46802857)
101. Jeon O, Lim HW, Lee M, Song SJ, Kim BS. Poly(l-lactide-co-glycolide) nanospheres conjugated with a nuclear localization signal for delivery of plasmid DNA. J. Drug Target. 15, 190-198 (2007). (Pubitemid 46562631)
102. Rafat M, Cleroux CA, Fong WG et al. PEG-PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells. Biomaterials 31, 3414-3421 (2010).
103. Zhang C, Wang YS, Wu H et al. Inhibitory efficacy of hypoxia-inducible factor 1a short hairpin RNA plasmid DNA-loaded poly (dl-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model. Gene Ther. 17, 338-351 (2009).
104. Jeong JH, Kim SW, Park TG. Biodegradable triblock copolymer of PLGA-PEG-PLGA enhances gene transfection efficiency. Pharm. Res. 21, 50-54 (2004). (Pubitemid 38122291)
105. Chang CW, Choi D, Kim WJ et al. Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle. J. Control. Release. 118, 245-253 (2007). (Pubitemid 46331900)
106. Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm. Res. 22, 1-10 (2005). (Pubitemid 40558140)